How a big biotech’s start-up gamble went wrong
Illumina, the world’s biggest gene sequencing company, announced plans to buy cancer detection start-up Grail for $8bn while the biotech boom was in full swing. To Illumina, Grail looked like a potent...
28 Jun 202323min
The downfall of a UK hedge fund titan
For decades, Crispin Odey sat atop the UK’s hedge fund scene. Lauded by many in financial circles as a charismatic maverick and known for taking high-risk bets on the market, he seemed untouchable. Un...
21 Jun 202324min
Is crypto a security, bro?
Crypto is at a crossroads. As exchanges and currencies blow up, the US Securities and Exchange Commission is ready to step in. But is crypto a security, like a stock? Or a tradable item of speculation...
16 Jun 202315min
Is Africa’s debt cycle unbreakable?
Ghana was once considered a success story and a model for African development. But after suffering several economic shocks, the west African country is now struggling to pay off its debts. The FT’s we...
14 Jun 202317min
Introducing Unhedged
We want to tell you about a new podcast coming soon! On Unhedged, Ethan Wu, Katie Martin and other markets nerds at the Financial Times explain the big ideas behind what’s happening in finance right n...
12 Jun 202358s
Libor's long goodbye
At one time not that long ago, you could find Libor in everything: mortgages, corporate loans, credits cards and more. Now, its days are numbered. The FT’s Harriet Clarfelt and Philip Stafford take us...
7 Jun 202316min
Best Of: Inside Johnson & Johnson’s bankruptcy two-step
This week, we’re revisiting an episode from last year. Johnson & Johnson, one of the world’s largest healthcare companies, is facing thousands of lawsuits from people alleging they got cancer from...
31 Mai 202334min
Does anyone want a digital euro?
As cryptocurrencies have grown in popularity and people use cash less and less, central banks have been put on the defensive. Their solution to stay relevant and maintain control? A central bank digit...
24 Mai 202320min
